Remicade (infliximab) is an antibody pharmaceutical. Infliximab was first approved as Remicade on 1998-08-24. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis in the USA. It has been approved in Europe to treat ankylosing spondylitis, crohn disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
|Indication||ankylosing spondylitis, crohn disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis|
|Drug Class||Monoclonal antibodies: chimeric, immunomodulating|